Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketanserin for sublingual microcirculation in severe sepsis
NCT01329887Phase 3Completed
- Sponsor
- Frisius Medisch Centrum
- Start
- Mar 2011
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ketanserin in sepsis and septic shock, sponsored by Frisius Medisch Centrum. Primary endpoint: Sublingual Microcirculation at 2 hours. Started Mar 2011; status: completed.
02
Drugs
ketanserin
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT01329887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01329887.